Total for the last 12 months
number of access : ?
number of downloads : ?
ID 113046
Author
Ono, Michihiro Sapporo Medical University
Takimoto, Rishu Sapporo Medical University
Osuga, Takahiro Sapporo Medical University
Okagawa, Yutaka Sapporo Medical University
Hirakawa, Masahiro Sapporo Medical University
Yoshida, Makoto Sapporo Medical University
Arihara, Yohei Sapporo Medical University
Uemura, Naoki Sapporo Medical University
Hayasaka, Naoki Sapporo Medical University
Miura, Shogo Sapporo Medical University
Matsuno, Teppei Sapporo Medical University
Tamura, Fumito Sapporo Medical University
Sato, Tsutomu Sapporo Medical University
Iyama, Satoshi Sapporo Medical University
Miyanishi, Koji Sapporo Medical University
Takada, Kohichi Sapporo Medical University
Kobune, Masayoshi Sapporo Medical University
Kato, Junji Sapporo Medical University
Keywords
AML
Notch-1
targeting
liposome
L-fucose
Content Type
Journal Article
Description
Complete remission by induction therapy in acute myelogenous leukemia (AML) can be achieved due to improvements in supportive and optimized therapy. However, more than 20% of patients will still need to undergo salvage therapy, and most will have a poor prognosis. Determining the specificity of drugs to leukemia cells is important since this will maximize the dose of chemotherapeutic agents that can be administered to AML patients. In turn, this would be expected to lead to reduced drug toxicity and its increased efficacy. We targeted Notch-1 positive AML cells utilizing fucose-bound liposomes, since activation of Notch-1 is required for O-fucosylation. Herein, we report that intravenously injected, L-fucose-bound liposomes containing daunorubicin can be successfully delivered to AML cells that express fucosylated antigens. This resulted in efficient tumor growth inhibition in tumor-bearing mice and decreased proliferation of AML patient-derived leukemia cells. Thus, biological targeting by fucose-bound liposomes that takes advantage of the intrinsic characteristics of AML cells could be a promising new strategy for Notch-1 positive-AML treatment.
Journal Title
Oncotarget
ISSN
19492553
Publisher
Impact Journals, LLC
Volume
7
Issue
25
Start Page
38586
End Page
38597
Published Date
2016-05-23
Remark
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0)(https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences